Growth in Patient and Medical Community Engagement in NASH Community Persists Despite Recent Regulatory Disappointment
June 08, 2023 07:19 ET
|
Global Liver Institute
Washington, D.C., June 08, 2023 (GLOBE NEWSWIRE) -- Today is International NASH Day, a time where healthcare experts and community members around the globe step up and raise awareness of the most...
Sagimet Biosciences to Present Interim Data from Phase 2b Trial of Denifanstat in NASH at EASL Congress 2023
June 07, 2023 09:00 ET
|
Sagimet Biosciences Inc.
SAN MATEO, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways,...
Madrigal Pharmaceuticals Supports International NASH Day on June 8
June 06, 2023 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., June 06, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Madrigal Pharmaceuticals Announces Participation at Two Upcoming Investor Conferences
June 01, 2023 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., June 01, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Madrigal Pharmaceuticals Provides Corporate Updates and Reports First Quarter 2023 Financial Results
May 09, 2023 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
Resmetirom new drug application (NDA) filing on track for Q2 2023Resmetirom has received Breakthrough Therapy designation from FDA Multiple resmetirom abstracts accepted for presentation at EASL,...
ICER MIDWEST CEPAC WORKS TO KEEP UP WITH WELL-INFORMED NASH PATIENT ADVOCATES
May 01, 2023 17:36 ET
|
Global Liver Institute
Washington, DC, May 01, 2023 (GLOBE NEWSWIRE) -- On Friday, the Institute for Clinical and Economic Review (ICER) held a public hearing to review its draft assessment of Resmetirom and Obeticholic...
PATIENT GROUPS DECLARE ICER REVIEW OF NASH MEDICATIONS CAUSES MORE UNCERTAINTY AND CONTROVERSIES THAN IT RESOLVES
April 28, 2023 12:22 ET
|
Global Liver Institute
Washington, DC, April 28, 2023 (GLOBE NEWSWIRE) -- Today, the Institute for Clinical and Economic Review (ICER) will hold a public hearing on its draft assessment of Resmetirom and Obeticholic Acid...
Madrigal Receives Breakthrough Therapy Designation from FDA for Resmetirom and Completes Enrollment of the Phase 3 MAESTRO-NASH Biopsy Trial
April 18, 2023 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., April 18, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...
Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results
February 23, 2023 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
Positive Phase 3 MAESTRO-NASH study results reported in December 2022 position Madrigal for a resmetirom new drug application filing in the first half of 2023Madrigal reports year end cash, cash...
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
February 08, 2023 08:00 ET
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic...